@article{Nicola Gökbuget_Hervè Dombret_Jose-Maria Ribera_Adele K. Fielding_Anjali Advani_Renato Bassan_Victoria Chia_Michael Doubek_Sebastian Giebel_Dieter Hoelzer_Norbert Ifrah_Aaron Katz_Michael Kelsh_Giovanni Martinelli_Mireia Morgades_Susan O’Brien_Jacob M. Rowe_Julia Stieglmaier_Martha Wadleigh_Hagop Kantarjian_2016, place={Pavia, Italy}, title={International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia}, volume={101}, url={https://haematologica.org/article/view/7909}, DOI={10.3324/haematol.2016.144311}, abstractNote={Adults with relapsed/refractory acute lymphoblastic leukemia have an unfavourable prognosis, which is influenced by disease and patient characteristics. To further evaluate these characteristics, a retrospective analysis of 1,706 adult patients with Ph-negative relapsed/refractory B-precursor acute lymphoblastic leukemia diagnosed between 1990–2013 was conducted using data reflecting the standard of care from 11 study groups and large centers in Europe and the United States. Outcomes included complete remission, overall survival, and realization of stem cell transplantation after salvage treatment. The overall complete remission rate after first salvage was 40%, ranging from 35%–41% across disease status categories (primary refractory, relapsed with or without prior transplant), and was lower after second (21%) and third or greater (11%) salvage. The overall complete remission rate was higher for patients diagnosed from 2005 onward (45%, 95% CI: 39%–50%). One- and three-year survival rates after first, second, and third or greater salvage were 26% and 11%, 18% and 6%, and 15% and 4%, respectively, and rates were 2%–5% higher among patients diagnosed from 2005. Prognostic factors included younger age, longer duration of first remission, and lower white blood cell counts at primary diagnosis. This large dataset can provide detailed reference outcomes for patients with relapsed/refractory Ph-negative B-precursor acute lymphoblastic leukemia. <em><a href="http://clinicaltrials.gov">clinicaltrials.gov</a> identifier: 02003612</em&gt;}, number={12}, journal={Haematologica}, author={Nicola Gökbuget and Hervè Dombret and Jose-Maria Ribera and Adele K. Fielding and Anjali Advani and Renato Bassan and Victoria Chia and Michael Doubek and Sebastian Giebel and Dieter Hoelzer and Norbert Ifrah and Aaron Katz and Michael Kelsh and Giovanni Martinelli and Mireia Morgades and Susan O’Brien and Jacob M. Rowe and Julia Stieglmaier and Martha Wadleigh and Hagop Kantarjian}, year={2016}, month={Nov.}, pages={1524-1533} }